Recombinant bovine GPR37L1 is engineered for high yield and specificity:
GPR37L1 is implicated in diverse physiological processes:
Neurological Regulation: Modulates cerebellar development, Bergmann glia maturation, and glutamate homeostasis .
Cardiovascular Control: Regulates blood pressure homeostasis via central mechanisms .
Neuroprotection: Binds prosaposin/prosaptide to reduce oxidative stress in astrocytes .
Epilepsy and Migraine: Rare variants correlate with progressive myoclonus epilepsy and migraine .
Prosaposin/Prosaptide Binding: Activates Gαi-mediated pathways, inhibiting cAMP (EC₅₀ ~10 nM) and phosphorylating ERK1/2 .
Syntenin-1 Interaction: Enhances plasma membrane trafficking by 10-fold in heterologous systems .
Ion Transport: Regulates renal sodium reabsorption, linking to hypertension mechanisms .
Diagnostic Tools: Commercial ELISA kits enable GPR37L1 quantification in serum, plasma, and tissues .
Therapeutic Targets:
Drug Discovery: High-purity recombinant protein supports ligand screening and structural studies .
Expression Limitations: Poor native trafficking necessitates truncation or co-expression with syntenin-1 for functional studies .
Ligand Specificity: Despite prosaposin pairing, endogenous ligands in peripheral tissues remain unconfirmed .
Species-Specific Variations: Functional differences between bovine and human isoforms require further characterization .
Future research should prioritize crystallography to resolve bovine GPR37L1’s active-state structure and in vivo validation of its neuroprotective effects .